Treatment of CFS and Fibromyalgia With HRG 80 Red Ginseng

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04599348

Enrollment

Registered

2020-10-22

Start date

2020-10-14

Completion date

2021-04-30

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CFS, Fibromyalgia

Keywords

Ginseng

Brief summary

Will a unique form of ginseng be clinically helpful in those with chronic fatigue syndrome and fibromyalgia?

Detailed description

Ginseng has been shown in earlier studies to help fatigue in a number of conditions. But because of overharvesting, most ginseng is no longer have optimal levels of the active ginsenosides. A new technique has been developed to restore the level of active ginseng components those found in the wild ginseng used in earlier studies. This is available in a form called HRG 80 Red Ginseng. The study is an open pilot study to explore whether this treatment would be helpful for improving clinical function and symptomatology in chronic fatigue syndrome and fibromyalgia. Current clinical experience is suggesting that it may be.

Interventions

DIETARY_SUPPLEMENTHRG 80 Red Ginseng

A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Open label study

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. be diagnosed with CFS and/or fibromyalgia 2. live in the United States 3 - be over 18 years of age

Exclusion criteria

* Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Composite Visual analog scale of symptoms	6 weeks	Composite Score visual analog scale (0 - 30 Visual analog scale units , with 30 VAS units representing optimal function) of energy, cognition, and overall well-being. Each on a 0-10 scale with 10 being healthy. The units are the same for all 3 allowing them to be combined into a single composite total score. This total score (0-30 with 30 being the best outcome ) is the primary outcome measure

Secondary

Measure	Time frame	Description
VAS of pain and sleep	6 weeks	VAS of pain and sleep

Countries

United States

Contacts

Primary ContactJacob Teitelbaum, MD

FatigueDoc@gmail.com4105627409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026